Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4413762 | 1.00 | THRB (0.32) | THRBBLMPMP22KMT2AAPLNR | |
| SCHEMBL7238753 | 0.98 | APLNR (0.32) | KMT2AAPLNRFFAR3 | |
| SCHEMBL2208896 | 0.98 | APLNR (0.32) | KMT2AAPLNRFFAR3 | |
| SCHEMBL7238749 | 0.98 | APLNR (0.32) | KMT2AAPLNRFFAR3 | |
| Cadaverine Tartrate SCHEMBL7595119 | 0.79 | TSHR (0.33) | — | |
| Hydrochloric Acid SCHEMBL4422759 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL4415134 | 0.72 | — | — | |
| SCHEMBL11117818 | 0.69 | GRM6 (0.36) | APLNR | |
| SCHEMBL3935289 | 0.69 | — | — | |
| SCHEMBL7234181 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841066-B1 | ANTI-INFLUENZA AGENT CONJUGATED TO ANTI-INFLAMMATORY AGENT | ACADEMIA SINICA (TW) | 2021-02-17 | — | — | EP | disclosed |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| EP-2540726-B1 | Intermediates for the synthesis of E1 activity activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2546256-B1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3524272-A1 | ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY | Academia Sinica (TW) | 2019-08-14 | — | — | EP | disclosed |
| US-10130714-B2 | Enhanced anti-influenza agents conjugated with anti-inflammatory activity | ACADEMIA SINICA (TW) | 2018-11-20 | — | — | US | disclosed |
| EP-2540727-B1 | SULFAMOYLATING REAGENT | MILLENNIUM PHARM INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9802938-B2 | Sulfamoylating reagents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2178880-B1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARM INC (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-2540727-A1 | SULFAMOYLATING REAGENT | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-1040094-B1 | SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARM INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-6562861-B1 | (1R,3R,4R,1'S)-(-)-(1'-acetylamino-2 '-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50 less-than 1.mu.M). Bactericides or viricides | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-6495711-B2 | 1-(TERT-BUTOXYCARBONYLAMINO)-4-METHOXYCARBONYL-CYCLOPENT-2-ENE STARTING BY REACTING 2-AZABICYCLO(2.2.1)HEPT-5-EN-3-ONE WITH AN ALCOHOL AND NONAQUEOUS ACID; CHEMICAL INTERMEDIATES TO ANTIVIRAL AGENTS AGAINST INFLUENZA VIRUS | BIOCRYST PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020052524-A1 | Process for preparing (-)-(1S, 4R) N-protected 4-amino-2-cyclopentene-1-carboxylate esters | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-0434450-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1999-07-07 | — | — | EP | disclosed |
| EP-0921114-A1 | Intermediates to therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1999-06-09 | — | — | EP | disclosed |
| EP-0921121-A1 | Intermediates to therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1999-06-09 | — | — | EP | disclosed |
| EP-0434450-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130714-B2 | Enhanced anti-influenza agents conjugated with anti-inflammatory activity | NEU1, CTSA, CA7 | THRB 4672/4885BLM 4856/4885PMP22 4633/4885 |
| US-20020052524-A1 | Process for preparing (-)-(1S, 4R) N-protected 4-amino-2-cyclopentene-1-carboxylate esters | CPNE4, PYM1, CCNT1 | THRB 3706/4885BLM 4159/4885PMP22 1956/4885 |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, STS | THRB 3471/4885BLM 3635/4885PMP22 2879/4885 |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, ALDH18A1 | THRB 3508/4885BLM 3782/4885PMP22 2873/4885 |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | THRB 3480/4885BLM 3729/4885PMP22 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.